Company intelligence
Alveolus Bio
Harnessing the power of the live biotherapeutics and small molecules for the prevention and treatment of lung diseases
Biotechnology Research
Boston, US
8 employees
1 public signals
About Alveolus Bio
Alveolus Bio is a team of scientists, physicians, and innovators pioneering breakthrough FDA-approved therapeutics for lung diseases. Our pipeline includes preclinical stage live biotherapeutics for Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disease (COPD), and Non-Cystic Fibrosis Bronchiectasis (NCFBE). Inhaled delivery effectively targets the distal regions of the lungs, bypassing first-pass metabolism and enhancing efficacy while reducing adverse effects, differentiating our drugs from other treatments.
Verified activity
Signals from Alveolus Bio
1 published signal